Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors

Radiotherapy and Oncology

Volumn 88, Issue 2, 2008, Pages 177-182

  Combs, Stephanie E ^a   Nagy, Monika ^a   Edler, Lutz ^b   Rausch, Renate ^b   Bischof, Marc ^a   Welzel, Thomas ^a   Debus, Jürgen ^a   Schulz Ertner, Daniela ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anaplastic glioma; Chemotherapy; Outcome; Radiotherapy

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ALOPECIA; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NAUSEA; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 49149121324     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.03.005     Document Type: Article

References (41)

1. Mahaley Jr. M.S., Mettlin C., Natarajan N., Laws Jr. E.R., and Peace B.B. National survey of patterns of care for brain-tumor patients. J Neurosurg 71 (1989) 826-836
2. Kleihues P., Coons S.W., and Burger P.C. Astrocytic Tumors. In: Kleihues P.C.W. (Ed). World health organization classification of tumors. Pathology and genetics of tumors of the central nervous system (2000), IARC Press, Lyon, France 27-28
3. Donahue B., Scott C.B., Nelson J.S., Rotman M., Murray K.J., Nelson D.F., et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys 38 (1997) 911-914
4. van den B.M., Chinot O.L., and Cairncross J.G. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncology 5 (2003) 128-138
5. van den Bent M.J., Chinot O., Boogerd W., Bravo M.J., Taphoorn M.J., Kros J.M., et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Annals of Oncology 14 (2003) 599-602
6. Glass J., Hochberg F.H., Gruber M.L., Louis D.N., Smith D., and Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76 (1992) 741-745
7. Cairncross J.G., Ueki K., Zlatescu M.C., Lisle D.K., Finkelstein D.M., Hammond R.R., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90 (1998) 1473-1479
8. Macdonald D.R., Gaspar L.E., and Cairncross J.G. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 27 (1990) 573-574
9. Curran Jr. W.J., Scott C.B., Horton J., Nelson J.S., Weinstein A.S., Nelson D.F., et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 12 (1992) 219-227
10. Nitta T., and Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 75 (1995) 2727-2731
11. Walker M.D., Strike T.A., and Sheline G.E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5 (1979) 1725-1731
12. Walker M.D., Green S.B., Byar D.P., Alexander Jr. E., Batzdorf U., Brooks W.H., et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303 (1980) 1323-1329
13. Combs S.E., Gutwein S., Schulz-Ertner D., van Kampen M., Thilmann C., Edler L., et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 181 (2005) 372-377
14. Stupp R., Mason W.P., Van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
15. Combs S.E., Gutwein S., Schulz-Ertner D., van Kampen M., Thilmann C., Edler L., et al. Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 181 (2005) 372-377
16. Stupp R., Mason W.P., Van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
17. Combs S.E., Wagner J., Bischof M., Welzel T., Edler L., Rausch R., et al. Radiochemotherapy In Patients with Primary Glioblastoma Comparing Two Temozolomide Dose Regimens. Int J Radiat Oncol Biol Phys (2008)
18. Stupp R., Mason W.P., Van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
19. Combs S.E., Thilmann C., Edler L., Debus J., and Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23 (2005) 8863-8869
20. Combs S.E., Widmer V., Thilmann C., Hof H., Debus J., and Schulz-Ertner D. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104 (2005) 2168-2173
21. Clark T.G., Bradburn M.J., Love S.B., and Altman D.G. Survival analysis part I: basic concepts and first analyses. Br J Cancer 89 (2003) 232-238
22. Clark T.G., Bradburn M.J., Love S.B., and Altman D.G. Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer 89 (2003) 781-786
23. Machin D., Campbell M., Fayers P., and Pinol A. Sample size tables for clinical studies. 2nd ed. (1997), Blackwell Sicnece, Malden, MA
24. Bain L.J., and Engelhardt M. Statistical analysis of reliability and life-testing models (1991), Marcel Dekker, New York
25. Desu M.M., and Raghavarao D. Sample size methodology (1990), Academic Press, New York
26. Vuorinen V., Hinkka S., Farkkila M., and Jaaskelainen J. Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien.) 145 (2003) 5-10
27. Walker M.D., Alexander Jr. E., Hunt W.E., MacCarty C.S., Mahaley Jr. M.S., Mealey Jr. J., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49 (1978) 333-343
28. Laperriere N., Zuraw L., and Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64 (2002) 259-273
29. Do V., Gebski V., and Barton M.B. The effect of waiting for radiotherapy for grade III/IV gliomas. Radiother Oncol 57 (2000) 131-136
30. Keime-Guibert F., Chinot O., Taillandier L., Cartalat-Carel S., Frenay M., Kantor G., et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 356 (2007) 1527-1535
31. Shapiro W.R., Green S.B., Burger P.C., Mahaley Jr. M.S., Selker R.G., VanGilder J.C., et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 71 (1989) 1-9
32. Brada M., Sharpe G., Rajan B., Britton J., Wilkins P.R., Guerrero D., et al. Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int J Radiat Oncol Biol Phys 43 (1999) 287-292
33. Stupp R., Mason W.P., Van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
34. Stupp R., Mason W.P., Van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
35. Weller M., Muller B., Koch R., Bamberg M., and Krauseneck P. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol 21 (2003) 3276-3284
36. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
37. Cairncross G, Seiferheld W, Shaw E, et al. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas. Initial report of RTOG 9402. J Clin Oncol 2004;22:107s.
38. Cairncross G, Seiferheld W, Shaw E, et al. Intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma: Initial report of RTOG 94-02. Presented at the Society of Neuro-Oncology 9th Annual Scientific Meeting, Toronto, Canada. November 18-21, 2004.
39. van den Bent MJ, Delattre JY, Brandes AA, et al. First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. Presented at the American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL. May 13-17, 2005.
40. Jaeckle K.A., Ballman K.V., Rao R.D., Jenkins R.B., and Buckner J.C. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol 24 (2006) 1246-1252
41. Vogelbaum M, Berkey B, Peerenboom D, et al. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas. J Clin Oncol 2005;23:119s (abstr 1520).